# Nephros Inc: Form 10-Q for the period ended Sep 30, 2013

- Company: [Nephros Inc](/companies/neph.md) (CIK 1196298)
- Form: 10-Q
- Filed: 2013-11-14
- Accepted by EDGAR: Nov 14, 2013, 16:01 ET
- Period: 2013-09-30
- Accession: 0001144204-13-061818
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1196298/000114420413061818/v356659_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1196298/000114420413061818/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-07-01 to 2013-09-30 | $418.0k | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2013-01-01 to 2013-09-30 | $1.5m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2013-07-01 to 2013-09-30 | $189.0k | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2013-01-01 to 2013-09-30 | $610.0k | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2013-07-01 to 2013-09-30 | $229.0k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2013-01-01 to 2013-09-30 | $904.0k | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2013-07-01 to 2013-09-30 | $578.0k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2013-01-01 to 2013-09-30 | $2.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2013-07-01 to 2013-09-30 | −$608.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2013-01-01 to 2013-09-30 | −$2.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2013-07-01 to 2013-09-30 | $5.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2013-01-01 to 2013-09-30 | $52.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2013-07-01 to 2013-09-30 | −$611.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2013-01-01 to 2013-09-30 | −$2.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2013-07-01 to 2013-09-30 | −$0.03 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2013-01-01 to 2013-09-30 | −$0.17 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2013-01-01 to 2013-09-30 | −$2.9m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Cash and equivalents | at 2013-09-30 | $168.0k | us-gaap:Cash |
| Current assets | at 2013-09-30 | $600.0k | us-gaap:AssetsCurrent |
| Total assets | at 2013-09-30 | $2.6m | us-gaap:Assets |
| Current liabilities | at 2013-09-30 | $1.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2013-09-30 | $2.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2013-09-30 | $430.0k | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1196298/000114420413061818/v356659_10q.htm

Filed Nov 14, 2013.
Source: SEC EDGAR, the filing index for accession 0001144204-13-061818. Last ingested by Listed: Nov 13, 2026, 16:20 ET. No prices; not investment advice.
